How have BCT shares performed in 2024?

BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of the year. Since then, BCT shares have increased by 0.0% and is now trading at C$10.60. View the best growth stocks for 2024 here .

What other stocks do shareholders of BriaCell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI) , Gene Biotherapeutics (CRXM) , Organovo (ONVO) , Anavex Life Sciences (AVXL) , Actinium Pharmaceuticals (ATNM) , Cytokinetics (CYTK) , Genmab A/S (GNMSF) , Inovio Pharmaceuticals (INO) , Medidata Solutions (MDSO) .

How do I buy shares of BriaCell Therapeutics?

Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor , Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. Compare Top Brokerages Here .

CVE:BCT

BriaCell Therapeutics (BCT) Stock Price, News & Analysis

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Free BCT Stock Alerts

C$10.60

-0.42 (-3.81%)

(As of 12/30/2021)

Compare

Today's Range: C$10.60
▼
C$11.07
50-Day Range: C$10.60
▼
C$10.60
52-Week Range: C$3.50
▼
C$15.75

Volume: 3,402 shs
Average Volume: 12,671 shs
Market Capitalization: C$168.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get BriaCell Therapeutics alerts:

Ad InvestorPlace

Elon Musk’s ChatGPT Could Soon Mint New Millionaires

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

About BriaCell Therapeutics Stock (CVE:BCT)

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

BCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCT Stock News Headlines

April 7, 2024 | americanbankingnews.com

BriaCell Therapeutics (CVE:BCT) Trading Down 3.8%

February 29, 2024 | ca.finance.yahoo.com

BriaCell Therapeutics Corp. (BCT.TO)

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

February 7, 2024 | msn.com

BriaCell shares rise on strong data from breast cancer treatment study

February 7, 2024 | markets.businessinsider.com

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

February 6, 2024 | marketwatch.com

BriaCell Shares Advance as Production of Lead Candidate Begins

December 28, 2023 | finanznachrichten.de

BriaCell Therapeutics Corp.: BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

December 28, 2023 | markets.businessinsider.com

BriaCell's Bria-IMT Regimen Shows 71% Intracranial ORR In Breast Cancer Patients

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

December 20, 2023 | markets.businessinsider.com

BriaCell Therapeutics Reports Preliminary Survival Benefit Data In Bria-IMT Regimen

December 1, 2023 | finance.yahoo.com

Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

November 3, 2023 | finance.yahoo.com

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

October 18, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp flat on Tuesday (BCT)

October 6, 2023 | stockhouse.com

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT(TM) in Advanced Breast Cancer

October 3, 2023 | finance.yahoo.com

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer

September 27, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp up on Tuesday (BCT)

September 8, 2023 | markets.businessinsider.com

BriaCell Therapeutics (BCT) Initiated with a Buy at H.C. Wainwright

August 17, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp down on Wednesday (BCT)

August 16, 2023 | finance.yahoo.com

BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS™ Immunotherapy for Cancer

May 30, 2023 | finance.yahoo.com

BriaCell Therapeutics Corp. CEO is Featured in an Interview With SmallCapsDaily

May 25, 2023 | finanznachrichten.de

BriaCell Therapeutics Corp.: BriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.

May 6, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp down on Friday (BCT)

April 26, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp down on Tuesday (BCT)

April 25, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp down on Monday (BCT)

April 21, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp up on Thursday (BCT)

April 17, 2023 | baystreet.ca

Positive Developments for Breast Cancer Care Attracting Big Investor Attention

April 15, 2023 | theglobeandmail.com

Closing Bell: Briacell Therapeutics Corp up on Friday (BCT)

See More Headlines

Receive BCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: CVE
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: CVE:BCT
CUSIP: N/A
CIK: N/A
Web: www.briacell.com
Phone: +1-604-9211810
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 129.63
Quick Ratio: 128.68

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: C$3.34 per share
Price / Cash Flow: 3.17
Book Value: C$3.60 per share
Price / Book: 2.94

Miscellaneous

Outstanding Shares: 15,913,000
Free Float: N/A
Market Cap: C$168.68 million
Optionable: Not Optionable
Beta: N/A

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. William V. Williams M.D. (Age 65)
CEO, Pres & Director
Comp: $283.44k
Dr. Charles Louis Wiseman M.D. (Age 75)
FACP, Founder
Comp: $73.1k
Mr. Gadi Levin B.Com. (Age 48)
C.A., M.B.A., CPA, MBA, CFO & Corp. Sec.
Comp: $52.5k
Ms. Farrah Dean
Mang. of Corp. Devel.

Key Competitors

View All Competitors

BCT Stock Analysis - Frequently Asked Questions

How have BCT shares performed in 2024?: BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of the year. Since then, BCT shares have increased by 0.0% and is now trading at C$10.60.
View the best growth stocks for 2024 here.
What other stocks do shareholders of BriaCell Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Gene Biotherapeutics (CRXM), Organovo (ONVO), Anavex Life Sciences (AVXL), Actinium Pharmaceuticals (ATNM), Cytokinetics (CYTK), Genmab A/S (GNMSF), Inovio Pharmaceuticals (INO), Medidata Solutions (MDSO).
How do I buy shares of BriaCell Therapeutics?: Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (CVE:BCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial